Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00439478
Status:
COMPLETED
Last Update Posted:
2007-11-14
First Post:
2007-02-22
Brief Title:
Dental Safety Profile of High-Dose Radioiodine Therapy
Sponsor:
University Hospital Basel Switzerland
Organization:
University Hospital Basel Switzerland
Study Overview
Official Title:
The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We aim to assess the incidence of oral and dental adverse events after high-dose radioiodine therapy for differentiated thyroid cancer
Detailed Description:
Sialadenitis and xerostomia are the most frequent adverse events of high-dose radioiodine therapy Saliva has vital functions in maintaining periodontal and oral health Therefore xerostomia not only impairs quality of life permanently but may also increase the risk of caries and tooth extractions Nevertheless despite more than 6 decades of radioiodine therapy for thyroid cancer large studies on long-term oral adverse events are still lacking In the present study we investigate the influence of high-dose radioiodine therapy on the long-term oral health
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None